How to manage inflammatory bowel disease during the COVID-19 pandemic:A guide for the practicing clinician  

作　　者：Júlio Maria Fonseca Chebli Natália Sousa Freitas Queiroz Adérson Omar Mourão Cintra Damião Liliana Andrade Chebli Márcia Henriques de Magalhães Costa Rogério Serafim Parra 

机构地区：[1]Division of Gastroenterology,Department of Medicine,Inflammatory Bowel Disease Center,Federal University of Juiz de Fora,Juiz de Fora 36036-900,MG,Brazil [2]Department of Gastroenterology,University of São Paulo School of Medicine,São Paulo 05403-000,SP,Brazil [3]Department of Clinical Medicine,Fluminense Federal University,Rio de Janeiro 24210-200,RJ,Brazil [4]Department of Surgery and Anatomy,Ribeirão Preto Medical School,University of São Paulo,Ribeirão Preto 14048-900,SP,Brazil

出　　处：《World Journal of Gastroenterology》2021年第11期1022-1042,共21页世界胃肠病学杂志（英文版）

摘　　要：Managing inflammatory bowel disease(IBD)during the coronavirus disease 2019(COVID-19)pandemic has been a challenge faced by clinicians and their patients,especially concerning whether to proceed with biologics and immunosuppressive agents in the background of a global outbreak of a highly contagious new coronavirus(severe acute respiratory syndrome coronavirus 2,SARS-CoV-2).The knowledge about the impact of this virus on patients with IBD,although it is still scarce,is rapidly evolving.In particular,concerns surrounding medications’impact for IBD on the risk of acquiring SARS-CoV-2 infection or developing COVID-19,and potentially exacerbate viral replication and the COVID-19 course,are a current thinking of both practicing clinicians and providers caring for patients with IBD.Managing patients with IBD infected with SARS-CoV-2 depends on both the clinical activity of the IBD and the occasional development and severity of COVID-19.In this review,we summarize the current data regarding gastrointestinal involvement by SARS-CoV-2 and pharmacologic and surgical management for IBD concerning this infection,and the COVID-19 impact on both the patient's psychological functioning and endoscopy services,and we concisely summarize the telemedicine roles during the COVID-19 pandemic.

关 键 词：Inflammatory bowel disease SARS-CoV-2 COVID-19 Crohn disease Colitis ulcerative Biological therapy 

分 类 号：R574[医药卫生—消化系统]